{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-006097","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.419894+00:00","generated_at":"2026-06-23T09:52:15.621544+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"BioCryst names Dr. Bill Sheridan CDO and Dr. Ryan Arnold CMO effective Sept 15, 2022","bullets":["Dr. William Sheridan transitions from CMO to Chief Development Officer, focusing on pipeline advancement.","Dr. Ryan Arnold promoted from SVP Global Medical Affairs (since March 2022) to Chief Medical Officer.","Both join Dr. Helen Thackray (Chief R&D Officer) as physicians on leadership team.","Dr. Sheridan joined BioCryst in 2008; Dr. Arnold has 20+ years industry experience including at Amgen, Genzyme, Biogen."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-006097","json":"https://secwatch.observer/filing/0001171843-22-006097.json","markdown":"https://secwatch.observer/filing/0001171843-22-006097.md","text":"https://secwatch.observer/filing/0001171843-22-006097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/f8k_091422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:52:15.621544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3008ef63b","claim":"Ryan Arnold was appointed as Chief Medical Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will serve"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"d8caf88f8b","claim":"William P. Sheridan changed role as Chief Development Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will serve"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}